JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kobayashi, M.
Right arrow Articles by Kawarabayashi, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kobayashi, M.
Right arrow Articles by Kawarabayashi, T.

Vol. 297, Issue 2, 666-671, May 2001

Pharmacological Characterization of KUR-1246, a Selective Uterine Relaxant

Mamoru Kobayashi , Keiko Takeda, Satoshi Murata, Masami Kojima, Masuo Akahane, Yoshihito Inoue, Kenji Kitamura and Tatsuhiko Kawarabayashi

Pharmacology Research, R&D, Kissei Pharmaceutical Co., Ltd., Nagano, Japan (M.K., K.T., S.M., M.K., M.A.); Department of Pharmacology, Fukuoka Dental College, Fukuoka, Japan (K.K.); and Department of Obstetrics and Gynecology, Fukuoka University School of Medicine, Fukuoka, Japan (Y.I., T.K.)

The aim of the present study was to evaluate the efficacy and beta 2-adrenoceptor (AR) selectivity of KUR-1246, a new uterine relaxant. Inhibition of spontaneous or drug-induced uterine contractions by KUR-1246 was evaluated in pregnant rats and rabbits by an organ bath method or by a balloon method. The selectivity of KUR-1246 was assessed simultaneously in organs isolated from late-pregnant rats. The affinity of KUR-1246 for human beta 1-, beta 2-, and beta 3-ARs was determined using two radioligands. KUR-1246 suppressed both spontaneous and drug-induced contractions in isolated uteri, the rank order of potency being isoproterenol > KUR-1246 > terbutaline > ritodrine. ICI-118551 (selective beta 2-AR antagonist) competitively antagonized the KUR-1246-induced inhibition of spontaneous uterine contractions, but CGP-20712A (selective beta 1-AR antagonist) and SR-58894A (selective beta 3-AR antagonist) did not. All beta -AR agonists tested produced significant inhibition of spontaneous uterine contractions in vivo: ED30 value for KUR-1246 was 0.13 µg/kg/min, a potency about 6 times and 400 times greater than that of terbutaline and ritodrine, respectively. In contrast, the positive chronotropic effect was minimal in KUR-1246-treated rats. KUR-1246 displaced radioligand binding to beta 1-, beta 2-, and beta 3-ARs, the pKi values being 5.75 ± 0.03, 7.59 ± 0.08, and 4.75 ± 0.03 for beta 1-, beta 2-, and beta 3-ARs, respectively. For the selectivity of KUR-1246 for human beta 2-AR, we obtained values of 39.2 ([IC50 for beta 1-AR]/[IC50 for beta 2-AR]) and 198.2 ([IC50 for beta 3-AR]/[IC50 for beta 2-AR]), indicating an apparently higher affinity for human beta 2-AR than for other beta -AR subtypes. The present study clearly demonstrated that KUR-1246 is a more selective beta 2-AR agonist than the drugs presently used for relaxing uterine muscle.


0022-3565/01/2972-0666$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.